ACETAMINOPHEN Drug Patent Profile

Which patents cover Acetaminophen, and when can generic versions of Acetaminophen launch?

Acetaminophen is a drug marketed by Rising, Aspiro, B Braun Medical, Baxter Hlthcare Corp, Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Inforlife, Mylan, Sandoz, Wockhardt Bio Ag, Zydus Pharms, Able, Acino Prods, Perrigo New York, Taro, Aurobindo Pharma, Granules, Heritage, Marksans Pharma, Ohm Labs, Perrigo, Sun Pharm Inds Ltd, Teva, Actavis Mid Atlantic, Chartwell, Chartwell Molecular, Dava Pharms Inc, Genus Lifesciences, Pai Holdings, Pharmobedient, Strides Pharma, Am Therap, Amneal Pharms Ny, Ani Pharms, Aurolife Pharma Llc, Duramed Pharms Barr, Elite Labs Inc, Everylife, Fosun Pharma, Halsey, Hibrow Hlthcare, Kv Pharm, Lederle, Mikart, Mutual Pharm, Puracap Pharm, Purepac Pharm, Rhodes Pharms, Roxane, Specgx Llc, Strides Pharma Intl, Superpharm, Usl Pharma, Valeant Pharm Intl, Vitarine, Warner Chilcott, Watson Labs, Watson Labs Florida, Whiteworth Town Plsn, Cent Pharms, Aurobindo Pharma Ltd, Bionpharma, Dr Reddys, Glenmark Pharms Ltd, L Perrigo Co, Lnk Intl Inc, Gavis Pharms, Wraser Pharms Llc, Boca Pharma Llc, and West-ward Pharm Corp. and is included in one hundred and forty-five NDAs. There is one patent protecting this drug.

This drug has seventeen patent family members in twelve countries.

The generic ingredient in ACETAMINOPHEN is acetaminophen; caffeine; dihydrocodeine bitartrate. There are sixty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acetaminophen; caffeine; dihydrocodeine bitartrate profile page.

DrugPatentWatch^® Generic Entry Outlook for Acetaminophen

Annual sales in 2022 were $10mm indicating the motivation for generic entry (peak sales were $30mm in 2005).

There have been seventeen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ACETAMINOPHEN

International Patents:	17
US Patents:	1
Applicants:	73
NDAs:	145
Finished Product Suppliers / Packagers:	97
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1,433
Patent Applications:	4,009
Drug Prices:	Drug price information for ACETAMINOPHEN
Drug Sales Revenues:	Drug sales revenues for ACETAMINOPHEN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ACETAMINOPHEN
What excipients (inactive ingredients) are in ACETAMINOPHEN?	ACETAMINOPHEN excipients list
DailyMed Link:	ACETAMINOPHEN at DailyMed

See drug prices for ACETAMINOPHEN

See drug sales revenues for ACETAMINOPHEN

Recent Clinical Trials for ACETAMINOPHEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Brigham and Women's Hospital	PHASE1
National Institutes of Health (NIH)	PHASE1
Mayo Clinic	PHASE4

See all ACETAMINOPHEN clinical trials

Medical Subject Heading (MeSH) Categories for ACETAMINOPHEN

Analgesics, Non-Narcotic

Antipyretics

Paragraph IV (Patent) Challenges for ACETAMINOPHEN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OFIRMEV	Injection	acetaminophen	650 mg/65 mL (10 mg/mL)	022450	1	2024-07-31
OFIRMEV	Injection	acetaminophen	1000 mg/100 mL (10 mg/mL)	022450	1	2011-04-07

US Patents and Regulatory Information for ACETAMINOPHEN

ACETAMINOPHEN is protected by one US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Elite Labs Inc	ACETAMINOPHEN AND CODEINE PHOSPHATE	acetaminophen; codeine phosphate	TABLET;ORAL	212418-001	Sep 10, 2019	AA	RX	No	No
Rhodes Pharms	ACETAMINOPHEN AND CODEINE PHOSPHATE	acetaminophen; codeine phosphate	TABLET;ORAL	089673-003	Feb 10, 1988		DISCN	No	No
Chartwell	ACETAMINOPHEN AND CODEINE PHOSPHATE	acetaminophen; codeine phosphate	SOLUTION;ORAL	089450-001	Oct 27, 1992		DISCN	No	No

International Patents for ACETAMINOPHEN

See the table below for patents covering ACETAMINOPHEN around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	2421522
Hungary	E026823
Denmark	2626068

Market Dynamics and Financial Trajectory for Acetaminophen

Last updated: February 19, 2026

What Are the Current Market Size and Key Drivers?

The global acetaminophen (paracetamol) market was valued at approximately $4.8 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 3.1% from 2023 to 2030, reaching an estimated $6.2 billion.

Key drivers include:

• High demand for over-the-counter (OTC) analgesics and antipyretics.
• Increased prevalence of pain and fever conditions, especially among aging populations and in developing regions.
• Expanding use in combination therapies for cold and flu remedies.

Market segmentation by application reveals:

• Pain management accounts for roughly 60% of sales.
• Fever reduction contributes to 30%.
• Other uses, such as in pediatric formulations and combination drugs, constitute the remaining 10%.

Regional markets display differing growth:

• North America presides with a 40% market share, driven by high healthcare spending and OTC drug consumption.
• Asia-Pacific shows the fastest growth rate at 4.2%, propelled by population size, rising healthcare infrastructure, and increasing OTC drug access.

How Does Regulatory Environment Influence Market Trends?

Regulatory policies significantly impact acetaminophen sales and R&D investments:

• The U.S. Food and Drug Administration (FDA) enforces dosage limits due to hepatotoxicity risks, capping individual doses at 650 mg for OTC formulations.
• The European Medicines Agency (EMA) restricts maximum daily doses for adults to 4 grams.
• Canada recommends a maximum of 3 grams per day for adults to reduce liver injury risk.

These regulations influence product formulations, limit high-dose offerings, and limit the development of concentrated formulations. They also prompt innovation in combination products with lower individual doses.

What Are the Key Competitive Landscape Features?

Primary companies dominate the market:

Company	Market Share (2022)	Notable Launches/Initiatives
Johnson & Johnson	25%	Introduction of new pediatric formulations
Bayer	20%	Expansion into combination cold remedies
Purdue Pharma	15%	Focus on low-dose formulations to meet regulatory standards
Others	40%	Multiple regional players with niche market shares

Patent expirations for several formulations between 2020 and 2025 open opportunities for generics. This has led to intensified price competition and increased reliance on brand differentiation through packaging, delivery methods, and combination therapies.

What Are the R&D and Innovation Trends?

Research focuses on:

• Safer delivery systems, such as extended-release formulations.
• Combining acetaminophen with other analgesics or anti-inflammatory agents to enhance efficacy.
• Developing lower hepatotoxicity profiles.
• Exploring alternative routes of administration, including transdermal patches and intranasal sprays.

Despite a mature market, innovation efforts aim to:

• Address safety concerns related to overdose and liver toxicity.
• Expand indications to include chronic pain and other conditions.

How Do Supply Chain Factors Affect the Market?

Supply chain stability is crucial:

• Raw material sourcing remains stable, with phenol derivatives being the primary precursor.
• Manufacturing disruptions have occurred during the COVID-19 pandemic but recovered by late 2021.
• Regulatory compliance and quality standards remain high, with batch testing and validation processes adding to costs.

Pricing is sensitive to raw material costs, exchange rates, and geopolitical stability in manufacturing countries.

What Is the Financial Outlook?

Profitability for manufacturers depends mainly on:

• Volume sales driven by OTC demand.
• Cost control in manufacturing, supply chain management.
• Strategic marketing to differentiate products amid generic competition.

The average selling price (ASP) for branded products remains higher than generics, but increasing generic penetration pressures margins.

Forecasts show a gradual decline in ASPs due to generic competition, offset somewhat by gains in emerging markets and innovation-driven premium products.

Key Takeaways

• The global acetaminophen market is mature, with steady growth driven by OTC demand and regional healthcare expansion.
• Regulatory restrictions influence product formulations, R&D efforts, and market entry strategies.
• Major players are competing on innovation, safety profiles, and regional expansion, with patent expirations opening the gates for generics.
• Supply chains recovered from pandemic disruptions, supporting stable availability.
• Financial performance hinges on balancing volume growth with pricing pressures and R&D investments in safety and new delivery methods.

FAQs

How are regulatory changes affecting acetaminophen formulations?

Regulations impose dose caps to minimize liver toxicity, restricting high-dose product development. Companies shift toward lower-dose formulations and combination therapies to comply and meet consumer needs.

What are the main patent expiration dates affecting the market?

Major patents for branded formulations expired between 2020 and 2025, enabling aggressive price competition from generics and branded generics.

Which regions show the fastest market growth?

Asia-Pacific exhibits the highest CAGR at approximately 4.2%, driven by rising healthcare infrastructure and demand for OTC medications.

What are the primary safety concerns linked to acetaminophen?

Hepatotoxicity and liver failure from overdose remain the chief safety issues, prompting regulatory dose restrictions and increased R&D for safer formulations.

How is innovation influencing the competitive landscape?

Product innovation centers on improved safety, extended-release formats, and combination drugs, helping firms differentiate amid intense generic competition.

References

[1] MarketWatch. (2023). Acetaminophen Market Size, Share & Trends Analysis. https://www.marketwatch.com/
[2] Grand View Research. (2023). Paracetamol (Acetaminophen) Market Analysis. https://www.grandviewresearch.com/
[3] FDA. (2022). Acetaminophen-related dosing guidelines. https://www.fda.gov/
[4] EMA. (2021). Safe use of paracetamol: Regulatory guidelines. https://www.ema.europa.eu/
[5] IQVIA. (2022). Global OTC Market Trends Report. https://www.iqvia.com/